• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发灶不明的癌,诊断为炎性乳腺癌,采用曲妥珠单抗和长春瑞滨成功治疗。

Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.

作者信息

Asakura Hirofumi, Takashima Hitoshi, Mitani Masahiro, Haba Reiji, Seo Reiko, Yokoe Koiku, Toyama Yoshihiro, Ohkawa Motoomi

机构信息

Department of Radiology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Kagawa 761-0793, Japan.

出版信息

Int J Clin Oncol. 2005 Aug;10(4):285-8. doi: 10.1007/s10147-005-0485-x.

DOI:10.1007/s10147-005-0485-x
PMID:16136377
Abstract

Occult breast cancer presenting with axillary lymph node metastases is uncommon, and inflammatory breast cancer (IBC), as a subtype, is quite rare. Here we describe a case of IBC, which arose as an unknown primary carcinoma; the patient presented with axillary lymph node metastasis, and was successfully treated with trastuzumab and vinorelbine. Specifically, a 55-year-old woman presented with right axillary lymphadenopathy. Although she underwent various examinations, the primary site of the disease was not revealed. Axillary lymph node dissection was performed, and the lesion was diagnosed as a poorly differentiated adenocarcinoma. The patient chose to be treated by alternative medicine. About 6 months later, she was referred to our hospital, due to marked bilateral neck and axillary lymph node swelling. She presented with diffuse right breast enlargement, redness, and peau d'orange. Computed tomography (CT) of the breast showed skin thickening and swelling of the right breast.F-18 Fluorodeoxyglucose positron emission tomography (FDG-PET) showed FDG uptake in the right breast. The patient was clinically diagnosed with IBC. Because overexpression of the human epidermal growth factor receptor 2 (HER2) was found in the specimen from her right axillary lymph node, she was treated with trastuzumab and vinorelbine. Two months after the start of chemotherapy, CT revealed a complete response in the lymph nodes, and the skin thickening and parenchymal edema of the right breast had improved. FDG-PET was also performed at this time, and revealed no FDG uptake in either the right breast or the lymph nodes.

摘要

以腋窝淋巴结转移为表现的隐匿性乳腺癌并不常见,而炎性乳腺癌(IBC)作为一种亚型则极为罕见。在此,我们描述一例IBC病例,其最初表现为原发灶不明的癌;该患者出现腋窝淋巴结转移,并接受曲妥珠单抗和长春瑞滨治疗后获得成功。具体情况如下,一名55岁女性因右侧腋窝淋巴结肿大就诊。尽管她接受了各种检查,但疾病的原发部位仍未明确。遂进行了腋窝淋巴结清扫术,术后病变被诊断为低分化腺癌。该患者选择采用替代医学进行治疗。大约6个月后,由于双侧颈部和腋窝淋巴结明显肿大,她被转诊至我院。她表现为右侧乳房弥漫性增大、发红及橘皮样改变。乳房计算机断层扫描(CT)显示右侧乳房皮肤增厚及肿胀。F-18氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)显示右侧乳房有FDG摄取。该患者临床诊断为IBC。由于在其右侧腋窝淋巴结标本中发现人表皮生长因子受体2(HER2)过表达,她接受了曲妥珠单抗和长春瑞滨治疗。化疗开始两个月后,CT显示淋巴结完全缓解,右侧乳房的皮肤增厚及实质水肿也有所改善。此时也进行了FDG-PET检查,结果显示右侧乳房及淋巴结均无FDG摄取。

相似文献

1
Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.原发灶不明的癌,诊断为炎性乳腺癌,采用曲妥珠单抗和长春瑞滨成功治疗。
Int J Clin Oncol. 2005 Aug;10(4):285-8. doi: 10.1007/s10147-005-0485-x.
2
18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.18-氟脱氧葡萄糖正电子发射断层扫描在炎性乳腺癌中的应用
World J Surg. 2003 Oct;27(10):1099-104. doi: 10.1007/s00268-003-6893-z. Epub 2003 Aug 18.
3
Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.Ⅱ-Ⅲ 期乳腺癌新辅助化疗期间 ¹⁸F-FDG PET/CT 早期评估腋窝反应:对腋窝手术处理的影响。
Ann Surg Oncol. 2013 Jul;20(7):2227-35. doi: 10.1245/s10434-013-2902-0. Epub 2013 Mar 1.
4
[Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].两例复发性乳腺癌伴区域淋巴结转移对曲妥珠单抗和紫杉醇治疗显示完全缓解
Gan To Kagaku Ryoho. 2006 Sep;33(9):1301-3.
5
18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.新辅助治疗两个周期后的18F-氟脱氧葡萄糖(FDG)PET/CT可预测HER2阴性乳腺癌的反应,但对HER2阳性乳腺癌无效。
Oncotarget. 2015 Oct 6;6(30):29388-95. doi: 10.18632/oncotarget.5001.
6
A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.一例 HER-2 阳性晚期炎性乳腺癌,伴浸润性微乳头状成分,曲妥珠单抗联合紫杉醇治疗后临床完全缓解。
Int J Clin Oncol. 2010 Dec;15(6):615-20. doi: 10.1007/s10147-010-0093-2. Epub 2010 May 15.
7
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.氟尿嘧啶、表柔比星和环磷酰胺联合多西他赛或长春瑞滨,联合或不联合曲妥珠单抗,作为乳腺癌辅助治疗:芬兰乳腺癌试验(FinHer Trial)的最终结果
J Clin Oncol. 2009 Dec 1;27(34):5685-92. doi: 10.1200/JCO.2008.21.4577. Epub 2009 Nov 2.
8
[Remarkable improvement in a patient with metastatic and locally advanced HER2-positive breast cancer treated with trastuzumab plus vinorelbine].
Gan To Kagaku Ryoho. 2012 Mar;39(3):445-9.
9
Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.曲妥珠单抗、紫杉醇和表柔比星新辅助治疗老年炎性乳腺癌患者获得成功。
Anticancer Res. 2010 Feb;30(2):581-5.
10
Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.新辅助化疗后乳腺癌患者的淋巴闪烁显像。前哨淋巴结阴性患者的诊断价值及检查
Nuklearmedizin. 2011;50(1):33-8. doi: 10.3413/nukmed-0320-10-05.

引用本文的文献

1
Magnetic resonance imaging and F-fludeoxyglucose positron emission tomography/computed tomography findings of retroperitoneal clear cell carcinoma with an unknown primary site: A case report.原发部位不明的腹膜后透明细胞癌的磁共振成像及氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描表现:一例报告
Front Med (Lausanne). 2022 Nov 1;9:1024008. doi: 10.3389/fmed.2022.1024008. eCollection 2022.
2
"Metastatic Cancer of Unknown Primary" or "Primary Metastatic Cancer"?“原发灶不明的转移性癌”还是“原发性转移性癌”?
Front Oncol. 2020 Jan 17;9:1546. doi: 10.3389/fonc.2019.01546. eCollection 2019.
3
Malignant pleural effusion and cancer of unknown primary site: a review of literature.

本文引用的文献

1
Diagnostic and therapeutic management of cancer of an unknown primary.原发灶不明癌症的诊断与治疗管理
Eur J Cancer. 2003 Sep;39(14):1990-2005. doi: 10.1016/s0959-8049(03)00547-1.
2
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.曲妥珠单抗和长春瑞滨作为HER2过表达转移性乳腺癌的一线治疗:多中心II期试验的临床结果、血清肿瘤标志物作为预测因素的分析以及心脏监测算法
J Clin Oncol. 2003 Aug 1;21(15):2889-95. doi: 10.1200/JCO.2003.02.018.
3
恶性胸腔积液与原发部位不明的癌症:文献综述
Ann Transl Med. 2019 Aug;7(15):353. doi: 10.21037/atm.2019.06.33.
Update on the management of inflammatory breast cancer.
炎性乳腺癌管理的最新进展。
Oncologist. 2003;8(2):141-8. doi: 10.1634/theoncologist.8-2-141.
4
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.曲妥珠单抗和紫杉醇术前治疗后序贯阿霉素/环磷酰胺辅助治疗HER2过表达的II期或III期乳腺癌:一项初步研究。
J Clin Oncol. 2003 Jan 1;21(1):46-53. doi: 10.1200/JCO.2003.03.124.
5
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.炎性乳腺癌中微血管密度、雌激素受体α、MIB-1、p53和c-erbB-2的表达
Clin Cancer Res. 2002 Dec;8(12):3857-62.
6
New drugs for breast cancer.治疗乳腺癌的新药。
Lancet. 2002 Sep 7;360(9335):790-2. doi: 10.1016/S0140-6736(02)09903-8.
7
Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience.炎性乳腺癌预后标志物与疾病转归的病例对照研究:一项独特的临床经验。
Breast J. 2001 Nov-Dec;7(6):398-404. doi: 10.1046/j.1524-4741.2001.07604.x.
8
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.曲妥珠单抗单药用于一线治疗HER2过表达转移性乳腺癌的疗效与安全性。
J Clin Oncol. 2002 Feb 1;20(3):719-26. doi: 10.1200/JCO.2002.20.3.719.
9
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.对于过度表达HER2的转移性乳腺癌,使用化疗加一种抗HER2单克隆抗体进行治疗。
N Engl J Med. 2001 Mar 15;344(11):783-92. doi: 10.1056/NEJM200103153441101.
10
Occult breast cancer: a challenge from a surgical perspective.隐匿性乳腺癌:外科视角下的一项挑战。
Surg Oncol. 1999 Jul;8(1):27-33. doi: 10.1016/s0960-7404(99)00016-x.